This Biotech June Catalyst: What Investors Need to Know Now
A major fund trimmed its stake in a biotech ahead of a June FDA milestone. This article explains what that means for ...
Learn which dividend ETFs are inexpensive and still offer reliable income. Compare fee structures and performance to choose cost-conscious options.
20,642 articlesA major fund trimmed its stake in a biotech ahead of a June FDA milestone. This article explains what that means for ...
A Kentucky GOP primary produced a win for a Trump-backed challenger, marking a new chapter in Trump’s hold on the par...
The Vatican issues Magnifica Humanitas, a landmark call for AI regulation and human-centric design. Anthropic partici...
Bitcoin has seen wild swings, but a bold forecast remains on the table. This article breaks down why some investors b...
As Anthropic prepares an IPO, history warns that sky-high private valuations rarely translate into smooth public-mark...
The UFO ETF surged on Virgin Galactic strength, but a heavy tilt toward a single stock raises concentration concerns....
In 2026, investors face the classic question of trying to beat the market or simply track it, as costs rise and fund ...
As AI demand drives 24/7 data-center power, investors pivot from solar bets to nuclear plays. The nuclear fund is del...
SpaceX's hypothetical IPO sent SPCX to the mid-180s, valuing the company near $2.44 trillion. Analysts warn the rally...
Hit TV shows can feel like gold mines, but reality check: the money from a kids’ series isn’t “never work again” weal...
When contractors mislabel parts intended for military use, it can quietly inflate costs and undermine trust. This art...
A Chinese regulator warned of a security backdoor in Anthropic's Claude Code, signaling tightened AI-tool oversight a...